Brandon Chen

ORCID: 0009-0003-5241-490X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • RNA Interference and Gene Delivery
  • DNA Repair Mechanisms
  • Neural dynamics and brain function
  • RNA modifications and cancer
  • Neural Networks and Applications
  • Genetics and Neurodevelopmental Disorders
  • Advanced Fluorescence Microscopy Techniques
  • DNA and Nucleic Acid Chemistry
  • Health Systems, Economic Evaluations, Quality of Life
  • Photoreceptor and optogenetics research
  • Ethics in Clinical Research
  • Biomedical Ethics and Regulation
  • Neuroscience and Music Perception

The University of Texas MD Anderson Cancer Center
2022-2024

City of Hope
2020

Rockefeller University
2019

Brooklyn College
2018

The Graduate Center, CUNY
2018

City University of New York
2018

Despite considerable research on the barriers to enrollment in cancer therapeutic trials, few studies have elicited from perspective of community physicians, who provide majority care. The purpose this study was characterize and facilitators trials as perceived by oncologists practices.Twenty semistructured interviews were conducted with at six sites affiliated City Hope National Medical Center March June 2018. Responses recorded digitally transcribed. Data analyzed using qualitative content...

10.1200/jop.19.00662 article EN JCO Oncology Practice 2020-04-02

Abstract Background Inactivation of α-thalassemia/mental retardation X-linked (ATRX) represents a defining molecular feature in large subsets malignant glioma. ATRX deficiency gives rise to abnormal G-quadruplex (G4) DNA secondary structures, enhancing replication stress and genomic instability. Building on earlier work, we evaluated the extent which pharmacological G4 stabilization selectively enhances damage cell death ATRX-deficient preclinical glioma models. Methods Using stabilizer...

10.1093/neuonc/noae248 article EN Neuro-Oncology 2024-11-21

Abstract Mutations in α-thalassaemia/mental retardation X-linked (ATRX) are a critical molecular marker for fatal high-grade glioma (HGG). Standard of care has remained stagnant the last 30 years, with no therapies approved specifically ATRX-deficient glioma. ATRX mutations give rise to abnormal DNA secondary G-quadruplex (G4) structures at GC-rich regions genome, altering genome-wide accessibility chromatin and enhancing damage. We aim use G4 stabilizers, class novel small molecule...

10.1093/neuonc/noad179.0915 article EN Neuro-Oncology 2023-11-01

Abstract α-thalassaemia/mental retardation X-linked (ATRX) mutations are a critical molecular marker for high-grade glioma (HGG). These lead to accumulations of abnormal DNA secondary G-quadruplex (G4) structures, thereby inducing replication stress and damage. As G4s arise at GC-rich regions (i.e., pericentromeric telomeric regions), ATRX-deficiency alters genome-wide accessibility chromatin causes transcriptional dysregulation. However, the genomic consequences this in context poorly...

10.1093/neuonc/noac209.343 article EN Neuro-Oncology 2022-11-01
Coming Soon ...